TIDMBXP
RNS Number : 7172Q
Beximco Pharmaceuticals Ltd
20 October 2023
20 October 2023
This announcement contains inside information as stipulated
under the UK version of the Market Abuse Regulation 596/2014 which
is part of English Law by virtue of the European (Withdrawal) Act
2018, as amended. On publication of this announcement via a
regulatory information service, this information is considered to
be in the public domain.
BEXIMCO PHARMACEUTICALS LIMITED
Notification of Preliminary Results and Annual General
Meeting
Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the
Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the
fast-growing manufacturer of generic pharmaceutical products and
active pharmaceutical ingredients, today announces information for
shareholders of the Company that the Board of Directors decided at
their meeting held on 19 October 2023. Please see further detail as
follows:
1. To recommend the approval The Audited Financial Statements
of the Financial Statements for the year ended 30 June 2023
for the year ended 30 have been approved. The full accounts
June 2023 are expected to be announced by
01 November 2023
2. Date & Time of 47 (th) 28 December 2023 at 10.30 A.M.
Annual General Meeting
("AGM") of the Company
for the year ended 30
June, 2023
3. Venue of AGM Virtual Platform
4. Proposed Dividend for 35% Cash Dividend (i.e. Tk 3.50
the year ended 30 June per Share)
2023
5. Record date 13 November 2023
Comparative Financial Disclosures:
Beximco Pharmaceuticals Limited (Stand-alone)
Particulars Year ended Year ended
30 June 2023 30 June 2022
Net Profit after Tax Tk. 4,588,008,908 Tk. 5,161,343,643
Earnings Per Share (EPS) Tk. 10.28 Tk. 11.57
Net Asset Value (NAV) Tk. 43,341,239,142 Tk. 40,315,738,301
Net Asset Value per share (NAVPS) Tk. 97.15 Tk. 90.37
Net Operating Cash Flow Per Share Tk. 12.96 Tk. 11.27
(NOCFPS)
Beximco Pharmaceuticals Limited and its Subsidiaries
(Consolidated)
Particulars Year ended Year ended
30 June 2023 30 June 2022
Net Profit after Tax Tk. 4,524,468,490 Tk. 4,998,628,197
Earnings Per Share (EPS) Tk. 10.34 Tk. 11.48
Net Asset Value (NAV) Tk. 43,680,703,738 Tk. 40,600,497,817
Net Asset Value per share (NAVPS) Tk. 97.91 Tk. 91.01
Net Operating Cash Flow Per Share Tk. 13.64 Tk. 11.69
(NOCFPS)
For further information please visit www.beximcopharma.com or
enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, Ext.20080
S M Rabbur Reza, Chief Operating Officer
Tel: +880 2 58611001, Ext.20111
Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext.20030
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0) 20 3368 3551 / 3555
SP Angel Corporate Finance LLP (Broker)
Matthew Johnson
Tel: +44 (0) 20 3470 0470
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0) 20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading manufacturer and exporter of
medicines based in Bangladesh. Since its inception in 1976, the
Company remains committed to health and wellbeing of people across
all the continents by providing access to contemporary medicines.
Company's broad portfolio of generics encompasses diverse delivery
systems such as tablets, capsules, liquids, semi-solids,
intravenous fluids, metered dose inhalers, dry powder inhalers,
sterile ophthalmic drops, insulins, prefilled syringes,
injectables, nebuliser solutions, oral soluble films etc. The
Company also undertakes contract manufacturing for multinational
and leading global generic pharmaceutical companies.
Beximco Pharma's state-of-the-art manufacturing facilities are
certified by global regulatory authorities of USA, Europe,
Australia, Canada, GCC and Latin America, among others and it has a
geographic footprint in more than 50 countries. More than 5,500
employees are driving the company towards achieving its aspiration
to be among the most admired companies in the world.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORGPGAWUUPWGCB
(END) Dow Jones Newswires
October 20, 2023 02:04 ET (06:04 GMT)
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From Apr 2024 to May 2024
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From May 2023 to May 2024
